My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are a last resort because they’re not FDA‑approved, can have serious quality/sterility and dosing variability risks, and insurers often won’t cover them. Try appeals and safer, approved alternatives first.

What to do next (practical steps)

1. Appeal the denial

• Ask your prescriber to submit a prior authorization and a peer‑to‑peer review. Many denials are reversed on appeal.
• I can help draft an appeal letter if you want wording your doctor can adapt.

1. Check manufacturer help and savings programs

• Wegovy (semaglutide) — Novo Nordisk offers Wegovy Savings Card for eligible commercially insured patients and Novo Nordisk Patient Assistance/Access Solutions for qualifying uninsured/low‑income patients. Contact Novo Nordisk Patient Support (NovoCare/Access Solutions) for details.
• If you qualify for Medicare/Medicaid, ask your provider about patient assistance programs or state resources; manufacturer coupons usually don’t apply to public insurance.

1. Consider other FDA‑approved alternatives (often safer than compounded product)

• Zepbound (tirzepatide) — FDA‑approved for weight management (newer drug, often effective).
• Saxenda (liraglutide 3.0 mg) — FDA‑approved for weight management.
• Ozempic (semaglutide) and Rybelsus (oral semaglutide) — approved for diabetes but sometimes used off‑label for weight loss; insurance coverage may be different. Ask your clinician which of these fits your medical history and whether one might be easier to get covered.

1. Short‑term cost options while you sort coverage

• GoodRx, Blink Health, RxSaver can reduce out‑of‑pocket cost for some branded drugs (check coupons for Ozempic/Rybelsus).
• Manufacturer programs (see #2) can sometimes supply medication during an appeal.

1. If you’re considering compounded GLP‑1s (caution)

• Compounded semaglutide/tirzepatide are unapproved by FDA: potency, purity, sterility, and storage are common concerns. The FDA has warned about quality and safety risks with compounded biologic/peptide products.
• If you still consider it, only use a pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) and ask for sterility testing and a Certificate of Analysis for each lot. Confirm the pharmacy follows USP <797>/<800> compounding standards.
• Discuss risks explicitly with your clinician and consider getting the drug tested independently when possible.

1. Other options to discuss with your clinician

• Weight management programs, behavioral interventions, anti‑obesity medications that are covered, or bariatric surgery if appropriate.
• Clinical trials of GLP‑1s/tirzepatide — search ClinicalTrials.gov for local studies that may supply study drug.

Summary recommendation

• First: appeal the Wegovy denial and contact Novo Nordisk’s patient support/savings.
• Second: explore other FDA‑approved medications (Zepbound, Saxenda, Ozempic/Rybelsus) that may be covered.
• Only consider compounded GLP‑1s after exhausting approved/covered options and only from a well‑accredited compounding pharmacy with full testing documentation.

If you want, tell me (1) which insurer denied it, (2) whether you have commercial or government insurance (Medicare/Medicaid), and (3) whether you want help drafting an appeal or locating accredited compounding pharmacies or patient assistance contacts — I can draft an appeal letter or pull together contact info.